GreenLight Biosciences shares are trading higher after Samsung Biologics and the company announced the completion of the first commercial-scale engineering run for the companies' mRNA production partnership.
GreenLight Biosciences Holdings, PBC, formerly Environmental Impact Acquisition Corp, is a biotechnology company. The Company is focused on Ribonucleic acid (RNA) research, design, and manufacturing for human, animal, and plant health. The Company has developed technology to create high-performing, natural ribonucleic acid (RNA) products to address global sustainability challenges and promote healthier plants, foods, and people. The Company is engaged in the cell-free biomanufacturing platform. This platform enables the making of complex biological molecules nucleic acids, peptides, carbohydrates, and many others which allows manufacturing products at a lower cost than traditional methods using fermentation. The platform is used to develop and commercialize products. The Company's pipeline for plant and animal health includes Colorado potato beetle, Botrytis cinerea, Varroa mites, Fungicides, Grapevine powdery mildew, Fusarium Head Blight (FHB), Lepidoptera, and Powdery mildew.